🔍 See what insiders are buying — free 7-day trial, no credit card required.
Get started →
LLY
NYSE
🇺🇸 US
Eli Lilly and Company
Pharmaceuticals
13Score
DipBuster Score™
$1,133.00
$27.95 (-2.41%)
Live price · Source: Yahoo
52-Week Position
$623.78
91% of range
$1,182.73
Beta
0.517
Low vol
Dividend
—
no income
Mkt Cap
N/A
total value
Mkt CapN/A
P/EN/A
DividendNone
Beta0.517
52W High$1,182.73
52W Low$623.78
🤖
Not a Dip — Score 13/100
Zone: Sell / Avoid
🔒 Unlock Pro
Valuation
P/E Ratio—
Mkt CapN/A
52W Position91% of range
EV/EBITDA—
Cash Flow
FCF Yield—
FCF / Share
Op. Cash Flow—
Margins
Gross Margin—
Op. Margin—
Net Margin—
Balance Sheet
Cash—
Total Debt—
Net Cash—
Dividend
Yield—
Annual / shNone
Beta0.517
🔒
FCF, margins & balance sheet data are hidden — create a free account to see them.
🕵️
Insider Buys
Track director & CEO open-market purchases
📊
Valuation Analysis
P/E, EV/EBITDA, DCF & NCAV metrics
📈
Financial Charts
Revenue, EBITDA, FCF & balance sheet trends
🤖
AI Analysis
Plain-English explanation of every key metric
Sign up free — charts & fundamentals included
Get financial charts, valuation data, dividends & news for Eli Lilly and Company free. Upgrade to Pro for insider signals & AI analysis.
Sponsored · FCA Regulated Broker
Hargreaves Lansdown
UK's #1 investment platform. ISA, SIPP, GIA. FCA regulated since 1981.
Capital at risk. Your investments can go down as well as up. Disclaimer
DipBuster Score™ Breakdown
Value & P/E
0/30
Dip Position
4/25
Momentum & Volume
4/25
Quality & Size
5/10
Insider Activity
0/10
Quick Take
⚪
Not a Dip
DipBuster Score: 13/100
📉
Weak momentum — price has been struggling lately.
Company Profile
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite o…
Sector
Pharmaceuticals
Market
🇺🇸 US
CEO
David A. Ricks
Staff
47,000 employees
Website